CureVac Shares Are Trading Higher After the Company Presented Its CVGBM Cancer Vaccine Results From Its Phase 1 Study of Glioblastoma at the ESMO 2024 Congress.
CureVac Shares Are Trading Higher After the Company Presented Its CVGBM Cancer Vaccine Results From Its Phase 1 Study of Glioblastoma at the ESMO 2024 Congress.
CureVac股票交易走高,因公司在2024年ESMO大會上發佈了CVGBm癌症疫苗在膠質母細胞瘤一期研究中的結果。
CureVac Shares Are Trading Higher After the Company Presented Its CVGBM Cancer Vaccine Results From Its Phase 1 Study of Glioblastoma at the ESMO 2024 Congress.
CureVac股票交易走高,因公司在2024年ESMO大會上發佈了CVGBm癌症疫苗在膠質母細胞瘤一期研究中的結果。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。